When adjusting the model also by treatment status, performance status, and tumor stage (Supplemental Figure S1), the HR for KRAS G12C was slightly lower (1.75, 95% CI 1.01–3.04) but still significant (p = 0.048). The gene discussed is KRAS; the disease is neoplasm.